ArticleBMC cancer2025
Mechanistic study of HIF-1α-mediated regulation of the Notch1 pathway in promoting radioresistance in head and neck squamous cell carcinoma: a comprehensive analysis based on bioinformatics and functional experiments.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- VEGF Expression in Head and Neck Squamous Cell Carcinoma: Association with TNM Staging and Tumor Progression.Current issues in molecular biology · 2026Article
- NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer.JCI insight · 2026Article
- A Novel Fibrosis-Integrated Nomogram for Predicting Survival in Oral Squamous Cell Carcinoma Patients with Oral Submucous Fibrosis: A Retrospective Cohort Study.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy remains a cornerstone in the treatment of head and neck squamous cell carcinoma (HNSCC), yet resistance to irradiation significantly impairs therapeutic outcomes. Hypoxia within the tumor microenvironment is a known contributor to radioresistance, largely mediated by hypoxia-inducible factor 1-alpha (HIF-1α). However, the downstream molecular mechanisms remain incompletely defined. This study aimed to investigate whether HIF-1α promotes radioresistance in HNSCC through activation of the Notch1 signaling pathway.
methodsTranscriptomic data from TCGA-HNSC were analyzed to identify differentially expressed genes between radiosensitive (n = 251) and radioresistant (n = 35) groups. Gene set enrichment analysis (GSEA) and Pearson correlation assessed pathway involvement. In vitro experiments using CAL27 and FaDu cell lines were conducted under normoxic and hypoxic conditions. HIF1A was silenced via shRNA, and Notch1 was overexpressed for rescue experiments. Clonogenic survival, γ-H2AX immunofluorescence, EdU incorporation, and apoptosis (Annexin V/PI) were measured post-irradiation (2 Gy).
resultsHIF1A and Notch1 pathway genes were upregulated in radioresistant tumors (p < 0.05). Hypoxia significantly increased HIF1A, NOTCH1, DLL4, and HES1 expression in vitro (p < 0.001). HIF1A knockdown reduced clonogenic survival (P < 0.001), increased γ-H2AX foci (p < 0.001), suppressed proliferation (p < 0.001), and elevated apoptosis (p < 0.001). Notch1 overexpression partially reversed these effects (all p < 0.01).
conclusionOur findings suggest that HIF-1α promotes radiotherapy resistance in HNSCC by activating the Notch1 signaling axis. Targeting this pathway may enhance radiosensitivity and provide a new strategy for overcoming hypoxia-driven resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.